Compare Akamai Technologies, Inc. (AKAM) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Akamai Technologies, Inc. vs BIO-TECHNE Corp — how do they compare? Akamai Technologies, Inc. trades at $116.84 (market cap $16.91B), while BIO-TECHNE Corp trades at $72.13 (market cap $11.24B). The key difference: Akamai Technologies, Inc. is the larger of the two by market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Akamai Technologies, Inc. pays none. Which is the better fit depends on your goals.
| AKAM | TECH | |
|---|---|---|
Market Cap | $16.91B | $11.24B |
Sector | Technology | Health |
52-Week High | $161.14 | $72.29 |
52-Week Low | $70.61 | $43.31 |
Enterprise Value | $22.89B | $11.32B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Akamai Technologies (AKAM) trades at $110.54, down 6.76% over 24 hours, reflecting recent volatility despite strong Q2 2026 earnings beats. The stock shows bearish technical signals with support at $105 and resistance at $115, while fundamentals reveal revenue growth to $4.21 billion in 2025 but declining net margins to 9.51%. Analyst sentiment is mixed with a consensus price target of $152.60, and news highlights AI-driven cloud demand boosting performance.
Outlook remains cautious due to margin pressures from infrastructure investments, though AI and cybersecurity growth offer upside. Risks include competitive threats and execution challenges. Investors should weigh solid cash flow against high P/E of 40.05, with institutional hold ratings at 49.02% suggesting neutral near-term momentum.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Akamai Technologies, Inc.
Akamai operates a content delivery network, or CDN, which entails locating servers at the edges of networks so its customers, which store content on Akamai servers, can reach their own customers faster, more securely, and with better quality. Akamai has over 325,000 servers distributed over 4,000 points of presence in more than 1,000 cities worldwide. Its customers generally include media companies, which stream video content or make video games available for download, and other enterprises that run interactive or high-traffic websites, such as e-commerce firms and financial institutions. Akamai also has a significant security business, which is integrated with its core web and media businesses to protect its customers from cyberthreats.
Read more on AKAM →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
